CPHD
CEPHEIDNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Sep. 16, 12:07 PM
    • C.R. Bard (NYSE:BCR) upgraded to Outperform from Market Perform by Wells Fargo.
    • DexCom (NASDAQ:DXCM) upgraded to Buy from Hold by Desjardins. Downgraded to Neutral from Buy with a $92 (1% downside risk) price target by BTIG Research.
    • Alimera Sciences (NASDAQ:ALIM) upgraded to Outperform from Market Perform by Cowen & Company.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $47 (13% downside risk) from $30.
    • Akorn (NASDAQ:AKRX) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $34 (19% upside) from $33.
    • Community Health Systems (NYSE:CYH) upgraded to Positive from Neutral by Susquehanna. Price target raised to $18 (66% upside).
    • AstraZeneca (NYSE:AZN) upgraded to Buy from Hold by Jefferies. Price target raised to GBX 5,800 (14% upside) from GBX 5,400. Downgraded to Neutral from Outperform with a GBX 5,200 (2% upside) price target by BNP Paribas.
    • McKesson (NYSE:MCK) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $189 (15% upside) from $210.
    • Cardinal Health (NYSE:CAH) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $83 (8% upside) from $90.
    • Novavax (NASDAQ:NVAX) downgraded to Neutral from Outperform by Wedbush. Price target lowered to $2 (44% upside) from $14. Downgraded to Neutral from Buy by Citigroup. Price target lowered to $1.50 (8% upside) from $12. Downgraded to Neutral from Overweight by JPMorgan and Piper Jaffray.
    • Raptor Pharmaceutical (NASDAQ:RPTP) downgraded to Market Perform from Outperform by Cowen & Company.
    • Vitae Pharmaceuticals (NASDAQ:VTAE) downgraded to Market Perform from Outperform by BMO Capital.
    • Atara Biotherapeutics (NASDAQ:ATRA) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $16 (18% downside risk) from $23.
    • GlaxoSmithKline (NYSE:GSK) downgraded to Underperform from Neutral with a GBX 1,520 (6% downside risk) price target by BNP Paribas.
    • Applied Genetic Technologies (NASDAQ:AGTC) downgraded to Neutral from Buy by Roth Capital. Price target lowered to $12 (34% upside) from $34. Downgraded to Hold from Buy by Cantor Fitzgerald. Price target lowered to $15 (68% upside) from $32.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Outperform by Baird.
    | Fri, Sep. 16, 12:07 PM | 8 Comments
  • Fri, Sep. 9, 9:59 AM
    • Eli Lilly (NYSE:LLY) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $95 (20% upside) from $92.
    • Ligand Pharmaceuticals (NASDAQ:LGND) upgraded to Hold from Sell by Deutsche Bank. Price target raised to $110 (2% downside risk) from $105.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Buy from Hold by Jefferies. Price target raised to $91 (16% upside). Morgan Stanley rates it Hold with a price target of $100 (27% upside).
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Market Perform with a $66 price target by Oppenheimer.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Overweight by JPMorgan.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Overweight with a $73 (14% upside) price target by JPMorgan.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Buy by BTIG Research.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) downgraded to Neutral from Buy by Roth Capital.
    • Momenta Pharmaceuticals (NASDAQ:MNTA) downgraded to Sell from Hold with a $6 (48% downside risk) price target by Maxim Group.
    • Biogen (NASDAQ:BIIB) downgraded to Hold from Buy with a $323 (7% upside) price target by Jefferies.
    • Centene (NYSE:CNC) downgraded to Market Perform from Outperform with an $80 (19% upside) price target by Leerink Swann. Wedbush rates it Outperform with an $85 (26% upside) price target.
    | Fri, Sep. 9, 9:59 AM | 12 Comments
  • Tue, Sep. 6, 3:00 PM
    | Tue, Sep. 6, 3:00 PM
  • Tue, Sep. 6, 12:45 PM
    | Tue, Sep. 6, 12:45 PM
  • Tue, Sep. 6, 9:14 AM
    | Tue, Sep. 6, 9:14 AM
  • Tue, Sep. 6, 7:05 AM
    • Danaher (NYSE:DHR) inks a deal with Cepheid (NASDAQ:CPHD) to acquire all the outstanding stock of the molecular diagnostics firm for $53 a share in cash (~$4B including debt less acquired cash). The transaction should close in Q4.
    • Danaher is a conglomerate of over 20 businesses that are managed under the auspices of the Danaher Business System. Its Life Sciences & Diagnostics segment includes Beckman Coulter, HemoCure, Leica Biosystems, Leica Microsystems, Molecular Devices, Pall, Radiometer and SCIEX.
    • CPHD is up 53% premarket on light volume.
    | Tue, Sep. 6, 7:05 AM
  • Thu, Jul. 28, 4:09 PM
    • CEPHEID (NASDAQ:CPHD): Q2 EPS of $0.05 beats by $0.05.
    • Revenue of $146M (+10.2% Y/Y) in-line.
    • Press Release
    | Thu, Jul. 28, 4:09 PM
  • Wed, Jul. 27, 5:35 PM
  • Thu, Jun. 30, 7:37 AM
    • The FDA approves the first test to detect certain genetic markers of bacteria that are resistant to carbapenem antibiotics, the typical drug used in hospitals to treat serious infections. The test, Xpert Carba-R Assay, was developed by molecular diagnostics outfit Cepheid (NASDAQ:CPHD). It generates results in 48 minutes compared to as long as four days for culture.
    • Xpert Carba-R detects five different genetic markers associated with the enzyme carbapenemase produced by carbapenem-resistant Enterobacteriaceae. The test is intended to be used as an aid in infection control and should be used in conjunction with other clinical and laboratory findings.
    | Thu, Jun. 30, 7:37 AM
  • Fri, Jun. 17, 6:53 AM
    • HCA Holdings (NYSE:HCA) initiated with Market Perform rating and $88 (13% upside) price target by Sanford C. Bernstein.
    • UnitedHealth Group (NYSE:UNH) initiated with Outperform rating and $142 (2% upside) price target by Sanford C. Bernstein.
    • Cepheid (NASDAQ:CPHD) initiated with Equal Weight rating and $30 (1% upside) price target by Morgan Stanley.
    • Amsurg (NASDAQ:AMSG) initiated with Market Perform rating by Wells Fargo.
    • Cynapsus Therapeutics (NASDAQ:CYNA) initiated with Buy rating and $24 (41% upside) price target by Janney Capital.
    • Entellus Medical (NASDAQ:ENTL) initiated with Buy rating and $22 (20% upside) price target by BTIG Research.
    • DENTSPLY SIRONA (NASDAQ:XRAY) initiated with Overweight rating and $70 (10% upside) price target by Piper Jaffray.
    | Fri, Jun. 17, 6:53 AM | 1 Comment
  • Thu, Apr. 28, 4:12 PM
    • CEPHEID (NASDAQ:CPHD): Q1 EPS of $0.08 beats by $0.07.
    • Revenue of $144.78M (+9.2% Y/Y) beats by $4.58M.
    • Shares +5.59%.
    | Thu, Apr. 28, 4:12 PM | 1 Comment
  • Wed, Apr. 27, 5:35 PM
  • Fri, Apr. 1, 11:25 AM
    • Cepheid (CPHD +6%) upgraded to Buy from Neutral by BTIG Research. Price target set at $42 (19% upside).
    • Cardiovascular Systems (CSII +28.1%) upgraded to Buy from Underperform by Needham. Price target set at $16 (20% upside).
    • United Health Services (UHS -0.6%) upgraded to Outperform from Market Perform by Wells Fargo.
    • PRA Health Services (PRAH +1.4%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $51 (17% upside) from $47.
    • Dimension Therapeutics (DMTX +3.1%) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $10 (25% upside) from $12.
    • Novartis (NVS -2%) downgraded to Neutral from Buy by UBS. Price target lowered to CHF72 (3% upside) from CHF100. Downgraded to Neutral from Buy by Citigroup.
    • Intuitive Surgical (ISRG -0.2%) downgraded to Neutral from Buy by BTIG Research.
    • ATyr Pharma (LIFE -1%) downgraded to Market Perform from Outperform by William Blair. Price target lowered to $8 (106% upside) from $42.
    • Achaogen (AKAO -1.4%) downgraded to Market Perform from Outperform by Cowen & Co.
    • Portola Pharmaceuticals (PTLA +4.1%) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $30 (40% upside) from $65.
    • Quintiles Transnational Holdings (Q +1.9%) downgraded to Neutral from Buy by SunTrust Robinson Humphrey.
    | Fri, Apr. 1, 11:25 AM | 1 Comment
  • Wed, Mar. 9, 9:17 AM
    • The FDA approves Cepheid's (NASDAQ:CPHD) Xpert Carba-R, a qualitative in vitro diagnostic test that identifies five distinct families of carbapenem resistance genes in pure bacterial isolates, the first test to be so designated. The group as a whole represents the most common carbapenem-resistant bugs worldwide. The isolates may be cultured from a range of clinical specimens, including blood cultures, urine, respiratory samples, abscesses and swab surveillance samples.
    • Bacteria resist the action of antibiotics by producing enzymes that break down the drug, in this case, carbapenemases. Resistance to carbapenem-class antibiotics (imipenem, ertapenem, meropenem, doripenem) is a serious concern because they are commonly used as antimicrobial drugs of last resort.
    • Shipments of Xpert Carba-R will commence later this month. It is the 20th test that can be performed on the company's GeneXpert system.
    | Wed, Mar. 9, 9:17 AM
  • Wed, Feb. 10, 4:57 PM
    • Cepheid (NASDAQ:CPHD) promotes EVP and Chief Operating Officer Warren Kocmond to President & COO. His expanded responsibilities now include Global Commercial Operations in addition to Manufacturing, Engineering, Technical Service and Customer Service. He will continue to report to Chairman and CEO John Bishop.
    | Wed, Feb. 10, 4:57 PM
  • Tue, Feb. 2, 4:06 PM
    • CEPHEID (NASDAQ:CPHD): Q4 EPS of $0.07 beats by $0.27.
    • Revenue of $147M (+11.8% Y/Y) in-line.
    | Tue, Feb. 2, 4:06 PM